COVID-19-ассоциированные психозы
Рекомендуемое оформление библиографической ссылки:
Захарова Н.В., Бравве Л.В., Костюк Г.П. COVID-19-ассоциированные психозы // Российский психиатрический журнал. 2023. №1. С. 75-90.
В научном обзоре с целью анализа сведений о распространенности, клинической картине и дифференциальной диагностике, а также о принципах лечения и оценки прогноза COVID-19-ассоциированных психозов были изучены и систематизированы имеющиеся к настоящему моменту научные данные. COVID-19-ассоциированные психозы – это психотические расстройства, возникающие на фоне инфицирования новой коронавирусной инфекцией с четкими диагностическими критериями: документально подтвержденная инфекция COVID-19; психотический эпизод зафиксирован в истории болезни с указанием на выявленную острую позитивную симптоматику, манифестирующую после или одновременно с инфекцией COVID-19. Этот термин претендует стать дискретной нозологической формой. Полученные знания о COVID-19-ассоциированных психозах помогут практикующим врачам эффективно и оперативно купировать подобные состояния.
Ключевые слова COVID-19-ассоциированные психозы; инфекционные психозы; нейроинвазия; психофармакотерапия
1. Smith CM, Komisar JR, Mourad A, Kincaid BR. COVID-19-associated brief psychotic disorder. BMJ Case Rep. 2020;13(8):e236940. DOI: https://doi.org/10.1136/bcr-2020-236940 2. Smith CM, Gilbert EB, Riordan PA, et al. COVID-19-associated psychosis: A systematic review of case reports. Gen Hosp Psychiatry. 2021;73:84–100. DOI: https://doi.org/10.1016/j.genhosppsych.2021.10.003 3. World Health Organization: coronavirus dashboard. 2022. URL: https://covid19.who.int/table (accessed on: 12.01.2023). 4. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–27. DOI: https://doi.org/10.1016/S2215-0366(20)30203-0 5. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–90. DOI: https://doi.org/10.1001/jamaneurol.2020.1127 6. Loch AA, Mota NB, Rössler W, Gattaz WF. Exacerbation of psychosis risk during the COVID-19 pandemic: The disproportionate impact on the lower income population. Psychiatry Res. 2022;307:114319. DOI: https://doi.org/10.1016/j.psychres.2021.114319 7. Brown E, Gray R, Lo Monaco S, et al. The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research. Schizophr Res. 2020;222:79–87. DOI: https://doi.org/10.1016/j.schres.2020.05.005 8. Rentero D, Juanes A, Losada CP, et al. New-onset psychosis in COVID-19 pandemic: a case series in Madrid. Psychiatry Res. 2020;290:113097. DOI: https://doi.org/10.1016/j.psychres.2020.113097 9. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 Psychosis: A potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics. 2020;61(5):551–5. DOI: https://doi.org/10.1016/j.psym.2020.05.012 10. Xie Q, Fan F, Fan XP, et al. COVID-19 patients managed in psychiatric inpatient settings due to first-episode mental disorders in Wuhan, China: clinical characteristics, treatments, outcomes, and our experiences. Transl Psychiatry. 2020;10(1):337. DOI: https://doi.org/10.1038/s41398-020-01022-x 11. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J Virol. 2000;74(19):8913–21. DOI: https://doi.org/10.1128/jvi.74.19.8913-8921.2000 12. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–83. DOI: https://doi.org/10.1016/S1474-4422(20)30221-0 13. Severance EG, Dickerson FB, Viscidi RP, et al. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull. 2011;37(1):101–7. DOI: https://doi.org/10.1093/schbul/sbp052 14. Gardner PJ, Moallef P. Psychological impact on SARS survivors: Critical review of the English language literature. Canadian Psychology/Psychologie canadienne. 2015;56(1):123–35. DOI: https://doi.org/10.1037/a0037973 15. Lewis A, Frontera J, Placantonakis DG, et al. Cerebrospinal fluid in COVID-19: A systematic review of the literature. J Neurol Sci. 2021;421:117316. DOI: https://doi.org/10.1016/j.jns.2021.117316 16. Sharifian-Dorche M, Huot P, Osherov M, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020;417:117085. DOI: https://doi.org/10.1016/j.jns.2020.117085 17. Kekelidze ZI, Gurina OI, Shport SV, et al. Psihicheskie narushenija i sostojanie gematojencefalicheskogo bar'era u pacientov s novoj koronavirusnoj infekciej. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(6):22–32. (In Russ.) DOI: http://doi.org/10.47877/1560-957X-2021-10603 18. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. DOI: http://doi.org/10.1016/j.bbi.2020.03.031 19. Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20. DOI: http://doi.org/10.1128/JVI.00127-20 20. Malashenkova IK, Krynskiy SA, Ogurtsov DP, et al. The relationship of morphometric changes of the brain with IL-6 levels, systemic inflammation and immune disturbances in the patients with schizophrenia. Procedia Computer Science. 2021;190:553–9. DOI: http://doi.org/10.1016/j.procs.2021.06.064 21. Zakharova NV, Zozulya SA, Sarmanova ZV, et al. [Features of the immune profile of schizophrenic patients with catatonic syndrome]. Zh. Nevrol. Psikhiatr. Im. SS Korsakova. 2020;120(6–2):46–53. (In Russ.) DOI: http://doi.org/10.17116/jnevro202012006246 22. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses. 2014;7(4):223–30. DOI: http://doi.org/10.3371/CSRP.MICU.020813 23. Park S, Miller BJ. Meta-analysis of cytokine and C-reactive protein levels in high-risk psychosis. Schizophr Res. 2020;226:5–12. DOI: http://doi.org/10.1016/j.schres.2019.03.012 24. D Agostino A, D'Angelo S, Giordano B, et al. Brief psychotic disorder during the national lockdown in Italy: an emerging clinical phenomenon of the COVID-19 pandemic. Schizophr Bull. 2021;47(1):15–22. DOI: http://doi.org/10.1093/schbul/sbaa112 25. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med. 1965;58(5):295–300. PMID: 14283879 26. Ellul M, Varatharaj A, Nicholson TR, et al. Defining causality in COVID-19 and neurological disorders. J Neurol Neurosurg Psychiatry. 2020;91(8):811–2. DOI: http://doi.org/10.1136/jnnp-2020-323667 27. Tariku M, Hajure M. Available evidence and ongoing hypothesis on corona virus (COVID-19) and psychosis: is corona virus and psychosis related? A narrative review. Psychol Res Behav Manag. 2020;13:701–4. DOI: http://doi.org/10.2147/PRBM.S264235 28. Goenka A, Michael BD, Ledger E, et al. Neurological manifestations of influenza infection in children and adults: results of a National British Surveillance Study. Clin Infect Dis. 2014;58(6):775–84. DOI: http://doi.org/10.1093/cid/cit922 29. Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75. DOI: http://doi.org/10.1128/JVI.00737-08 30. Almqvist J, Granberg T, Tzortzakakis A, et al. Neurological manifestations of coronavirus infections – a systematic review. Ann Clin Transl Neurol. 2020;7(10):2057–71. DOI: http://doi.org/10.1002/acn3.51166 31. Delorme C, Paccoud O, Kas A, et al. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020;27(12):2651–7. DOI: http://doi.org/10.1111/ene.14478 32. Kremer S, Lersy F, de Sèze J, et al. Brain MRI findings in severe COVID-19: a retrospective observational study. Radiology. 2020;297(2):E242–51. DOI: http://doi.org/10.1148/radiol.2020202222 33. Han Y, Yuan K, Wang Z, et al. Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. Transl Psychiatry. 2021;11(1):499. DOI: http://doi.org/10.1038/s41398-021-01629-8 34. Menninger KA. The schizophrenic syndrome as a product of acute infectious disease. Archives of Neurology And Psychiatry. 1928;20(3):464. DOI: http://doi.org/10.1001/ARCHNEURPSYC.1928.02210150024002 35. Yethindra V, Tagaev T. A case report of coronavirus disease (COVID-19). Authorea. 2020. DOI: http://doi.org/10.22541/au.158880210.04246573 36. Valdés-Florido MJ, López-Díaz Á, Palermo-Zeballos FJ, et al. Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. Rev Psiquiatr Salud Ment. 2020;13(2):90–4. DOI: http://doi.org/10.1016/j.rpsm.2020.04.009 37. Caan MP, Lim CT, Howard M. A Case of Catatonia in a Man With COVID-19. Psychosomatics. 2020;61(5):556–60. DOI: http://doi.org/10.1016/j.psym.2020.05.021 38. Rogers JP, David AS. A longer look at COVID-19 and neuropsychiatric outcomes. Lancet Psychiatry. 2021;8(5):351–2. DOI: http://doi.org/10.1016/S2215-0366(21)00120-6 39. Sen M, Yesilkaya UH, Balcioglu YH. SARS-CoV-2-associated first episode of acute mania with psychotic features. J Clin Neurosci. 2021;87:29–31. DOI: http://doi.org/10.1016/j.jocn.2021.02.012 40. Zyablov VA, Gusev MA, Chizhikov VS. Clinical features of first-episode psychoses during the COVID-19 pandemic. Consortium Psychiatricum. 2021;2(3):27–33. DOI: http://doi.org/10.17816/CP85 41. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130–40. DOI: http://doi.org/10.1016/S2215-0366(20)30462-4 42. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7(10):875–82. DOI: http://doi.org/10.1016/S2215-0366(20)30287-X 43. Parra A, Juanes A, Losada CP, et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res. 2020;291:113254. DOI: http://doi.org/10.1016/j.psychres.2020.113254 44. Iqbal Y, Al Abdulla MA, Albrahim S, et al. Psychiatric presentation of patients with acute SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. BJPsych Open. 2020;6(5):e109. DOI: http://doi.org/10.1192/bjo.2020.85 45. Dutta BK, Mani RN, Sharma S, et al. COVID-19-associated psychosis in Indian settings: A retrospective descriptive study. Ind Psychiatry J. 2021;30(Suppl 1):S25–8. DOI: http://doi.org/10.4103/0972-6748.328784 46. Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–27. DOI: http://doi.org/10.1016/S2215-0366(21)00084-5 47. Prokopovich GA, Vladykina TV, Sivashova MS, Zueva ON. Experience of the psychiatric and psychotherapy services of an infectious hospital in the context of the COVID-19 pandemic. V.M. Bekhterev Review of Psychiatry and Medical Psychology. V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology; 2021. No 1. p. 67–76. DOI: http://doi.org/10.31363/2313-7053-2021-1-67-76 48. Syunyakov TS, Sharaev MG, Savilov VB, et al. A comparison of regional brain volumes in older adults with and without history of COVID-19. Consortium Psychiatricum. 2022;3(1):76–87. DOI: http://doi.org/10.17816/CP145 49. Bravve LV, Zakharova NV. COVID-19-associated schizophrenia-like psychosis. Psychiatry. 2023;20(4):44–53. DOI: http://doi.org/10.30629/2618-6667-2022-20-4-44-53 50. GBD Results Tool. URL: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/27a7644e8ad28e739382d31e77589dd7 (accessed on: 01.03.2022). 51. Forero-Peña DA, Hernandez MM, Mozo Herrera IP, et al. Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect? J Med Virol. 2022;94(3):1154–61. DOI: http://doi.org/10.1002/jmv.27443 52. Yesilkaya UH, Sen M, Karamustafalioglu N. New variants and new symptoms in COVID-19: First episode psychosis and Cotard’s Syndrome two months after infection with the B.1.1.7 variant of coronavirus. Schizophr Res. 2022;243:315–6. DOI: http://doi.org/10.1016/j.schres.2021.06.001 53. Ignatova D, Krasteva K, Akabalieva K, Alexiev S. Post-COVID-19 psychosis: Cotard’s syndrome and potentially high risk of harm and self-harm in a first-onset acute and transient psychotic disorder after resolution of COVID-19 pneumonia. Early Interv Psychiatry. 2022;16(10):1159–62. DOI: http://doi.org/10.1111/eip.13254 54. Cuevas-Esteban J, Sanagustin D, Iglesias-González M. Catatonia: Back to the future of the neuropsychiatric syndrome. Med Clin. (Barc.). 2022;158(8):369–77. DOI: http://doi.org/10.1016/j.medcli.2021.10.015 55. Kotfis K, Williams Roberson S, Wilson JE, et al. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176. DOI: http://doi.org/10.1186/s13054-020-02882-x 56. Watson CJ, Thomas RH, Solomon T, et al. COVID-19 and psychosis risk: Real or delusional concern? Neurosci Lett. 2021;741:135491. DOI: http://doi.org/10.1016/j.neulet.2020.135491 57. Girgis RR, Lieberman JA. Anti-viral properties of antipsychotic medications in the time of COVID-19. Psychiatry Res. 2021;295:113626. DOI: http://doi.org/10.1016/j.psychres.2020.113626 58. Plaze M, Attali D, Prot M, et al. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. Int J Antimicrob Agents. 2021;57(3):106274. DOI: http://doi.org/10.1016/j.ijantimicag.2020.106274 59. Khosravi M. Candidate psychotropics against SARS-CoV-2: a narrative review. Pharmacopsychiatry. 2022;55(1):16–23. DOI: http://doi.org/10.1055/a-1551-3756 60. Weston S, Coleman CM, Haupt R, et al. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. J Virol. 2020;94(21):e01218–20. DOI: http://doi.org/10.1128/JVI.01218-20 61. Baller EB, Hogan CS, Fusunyan MA, et al. Neurocovid: Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020;61(6):585–96. DOI: http://doi.org/10.1016/j.psym.2020.05.013 62. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–300. DOI: http://doi.org/10.1001/jama.2020.22760 63. Jansen van Vuren E, Steyn SF, Brink CB, et al. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. Biomed Pharmacother. 2021;135:111200. DOI: http://doi.org/10.1016/j.biopha.2020.111200 64. Chacko M, Job A, Caston F 3rd, et al. COVID-19-Induced psychosis and suicidal behavior: case report. SN Compr Clin Med. 2020;2(11):2391–5. DOI: http://doi.org/10.1007/s42399-020-00530-7 65. Ostuzzi G, Papola D, Gastaldon C, et al. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med. 2020;18(1):215. DOI: http://doi.org/10.1186/s12916-020-01685-9 66. Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2017;7(7):CD009377. DOI: http://doi.org/10.1002/14651858.CD009377.pub3 67. Ostuzzi G, Gastaldon C, Papola D, et al. Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Ther Adv Psychopharmacol. 2020;10:2045125320942703. DOI: http://doi.org/10.1177/2045125320942703 68. Mohebbi N, Talebi A, Moghadamnia M, et al. Drug interactions of psychiatric and COVID-19 medications. Basic Clin Neurosci. 2020;11(2):185–200. DOI: http://doi.org/10.32598/bcn.11.covid19.2500.1 69. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, et al. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. Psychopharmacology (Berl.). 2021;238(2)329–40. DOI: http://doi.org/10.1007/s00213-020-05716-4 70. Mas Serrano M, Pérez-Sánchez JR, Portela Sánchez S, et al. Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. J Neurol Sci. 2020;415:116944. DOI: http://doi.org/10.1016/j.jns.2020.116944 71. Soh M, Hifumi T, Isokawa S, et al. Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020;38(10):e2243.e1–e3. DOI: http://doi.org/10.1016/j.ajem.2020.05.042 72. Sommer IE, Bakker PR. What can psychiatrists learn from SARS and MERS outbreaks? Lancet Psychiatry. 2020;7(7):565–6. DOI: http://doi.org/10.1016/S2215-0366(20)30219-4 73. Lim ST, Janaway B, Costello H, et al. Persistent psychotic symptoms following COVID-19 infection. BJPsych Open. 2020;6(5):e105. DOI: http://doi.org/10.1192/bjo.2020.76 74. Bourmistrova NW, Solomon T, Braude P, et al. Long-term effects of COVID-19 on mental health: A systematic review. J Affect Disord. 2022;299:118–25. DOI: http://doi.org/10.1016/j.jad.2021.11.031 75. Sönmez N, Romm KL, Andreasssen OA, et al. Depressive symptoms in first episode psychosis: a one-year follow-up study. BMC Psychiatry. 2013;13:106. DOI: http://doi.org/10.1186/1471-244X-13-106 76. Sicotte R, Iyer SN, Kiepura B, Abdel-Baki A. A systematic review of longitudinal studies of suicidal thoughts and behaviors in first-episode psychosis: course and associated factors. Soc Psychiatry Psychiatr Epidemiol. 2021;56(12):2117–54. DOI: http://doi.org/10.1007/s00127-021-02153-2 77. McGinty J, Upthegrove R. Depressive symptoms during first episode psychosis and functional outcome: A systematic review and meta-analysis. Schizophr Res. 2020;218:14–27. DOI: http://doi.org/10.1016/j.schres.2019.12.011 78. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603–5. DOI: http://doi.org/10.1001/jama.2020.12603 79. Negrini F, Ferrario I, Mazziotti D, et al. Neuropsychological Features of Severe Hospitalized Coronavirus Disease 2019 Patients at Clinical Stability and Clues for Postacute Rehabilitation. Arch Phys Med Rehabil. 2021;102(1):155–8. DOI: http://doi.org/10.1016/j.apmr.2020.09.376 80. Zolotovskaia IA, Shatskaia PR, Davydkin IL, Shavlovskaya OA. [Post-COVID-19 asthenic syndrome]. Zh. Nevrol. Psikhiatr. Im. SS Korsakova. 2021;121(4):25–30. (In Russ.) DOI: http://doi.org/10.17116/jnevro202112104125 81. Dean K, Murray RM. Environmental risk factors for psychosis. Dialogues Clin Neurosci. 2005;7(1):69–80. DOI: http://doi.org/10.31887/DCNS.2005.7.1/kdean 82. Radua J, Ramella-Cravaro V, Ioannidis JPA, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry. 2018;17(1):49–66. DOI: http://doi.org/10.1002/wps.20490 83. von Economo C. Encephalitis lethargica. Wiener klinische Wochenschrift. 1917;30:581–5. 84. Zakharova NV, Bonkalo TI, Bravve LV, et al. Semantic regulation of anxiety expectations during the COVID-19 pandemic: conspiracy trends. Health care of the Russian Federation. 2020;64(6):329–35. (In Russ.) DOI: http://doi.org/10.46563/0044-197X-2020-64-6-329-335 85. Wathelet M, Duhem S, Vaiva G, et al. Factors associated with mental health disorders among university students in france confined during the COVID-19 pandemic. JAMA Netw Open. 2020;3(10):e2025591. DOI: http://doi.org/10.1001/jamanetworkopen.2020.25591
Метрики статей
Metrics powered by PLOS ALM